NCT00819546 2026-03-25
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
39 trialsNCT06313437 2026-03-25
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03591510 2026-03-13
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Novartis
Phase 2 Active not recruiting
NCT02115295 2025-11-06
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03900949 2025-10-28
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04385290 2025-09-08
MOSAIC
Technische Universität Dresden
Phase 1/2 Recruiting
NCT03836209 2025-06-15
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
PrECOG, LLC.
Phase 2 Active not recruiting
NCT03280030 2025-03-20
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
Novartis
Phase 2 Completed
NCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT04027309 2024-12-17
HOVON 156 AML
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Active not recruiting
NCT04982354 2024-10-01
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT05219266 2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available
NCT03379727 2024-02-29
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Novartis
Phase 3 Completed
NCT04075747 2023-10-16
V-FAST
Jazz Pharmaceuticals
Phase 1 Completed
NCT03512197 2023-08-21
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Novartis
Phase 3 Completed
NCT05488613 2022-11-08
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
Novartis
Completed
NCT04496999 2022-10-06
HDMM
Insel Gruppe AG, University Hospital Bern
Phase 1 Terminated
NCT03951961 2022-01-21
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
University of Jena
Phase 2 Terminated
NCT00651261 2021-08-18
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT01883362 2021-03-17
RADIUS
Novartis
Phase 2 Completed
NCT00093600 2020-12-19
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Novartis
Phase 1 Completed
NCT02078609 2020-12-17
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Novartis
Phase 1 Completed
NCT01830361 2020-08-06
MIDOKIT
Technische Universität Dresden
Phase 2 Completed
NCT02624570 2020-07-15
AMLFLT3
Novartis
No longer available
NCT01477606 2020-06-04
Protocol in Acute Myeloid Leukemia With FLT3-ITD
University of Ulm
Phase 2 Completed
NCT03760445 2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2 Withdrawn
NCT03114228 2019-10-15
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
Novartis
No longer available
NCT01282502 2018-12-12
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT00782067 2018-11-15
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Novartis
Phase 2 Completed
NCT03207334 2018-10-22
iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)
University of Florida
Phase 2 Withdrawn
NCT01202877 2018-10-16
PKC412 and 5-Azacytidine
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01846624 2018-09-27
Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Stanford University
Phase 2 Terminated
NCT00233454 2018-09-20
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Stanford University
Phase 2 Completed
NCT00045942 2017-08-11
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
Novartis
Phase 1/2 Completed
NCT01174888 2016-07-06
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00866281 2015-12-22
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
Novartis
Phase 1/2 Terminated
NCT01920204 2015-01-19
Midostaurin in Indolent Systemic Mastocytosis
University Medical Center Groningen
Phase 2 Unknown
NCT01161550 2013-07-23
CLAG ATRA AML
Washington University School of Medicine
Phase 1 Completed
NCT01130662 2013-03-26
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
University of Kansas Medical Center
Phase 1 Completed